Wolfgang Stremmel, MD; Robert Ehehalt, MD; Frank Autschbach, MD; Max Karner, MD
Acknowledgment: The authors thank Susanne Schäfer for statistical analysis; Annika Braun, MD, and Alexandra Zahn, MD, for assistance in patient management; and Heather Karner, MA, for proofreading and editing services. They also thank Verena Schmieg and Anja Hanemann for assistance in assessing the follow-up data and Daniela Kautz and Anja Hanemann for assisting in the data management and graph generation.
Grant Support: By the Dietmar-Hopp Foundation (Dr. Stremmel).
Potential Financial Conflicts of Interest: Grants received: W. Stremmel (Dietmar-Hopp Foundation). Patents received: W. Stremmel (for retarded-release phosphatidylcholine as a mucoprotective agent for the large intestine.)
Reproducible Research Statement: The protocol (in German, with an English-language synopsis), data set, and statistical code are available to interested readers by contacting Dr. Stremmel (e-mail, email@example.com).
Requests for Single Reprints: Wolfgang Stremmel, MD, Department of Gastroenterology, University Hospital Heidelberg, Im Neuenheimer Feld 410, D-69120 Heidelberg, Germany; e-mail, firstname.lastname@example.org.
Current Author Addresses: Drs. Stremmel, Ehehalt, and Karner: Department of Gastroenterology, University Hospital Heidelberg, Im Neuenheimer Feld 410, D-69120 Heidelberg, Germany.
Dr. Autschbach: Pathological Institute, University Hospital Heidelberg, Im Neuenheimer Feld 220/221, 69120 Heidelberg, Germany.
Author Contributions: Conception and design: W. Stremmel, M. Karner.
Analysis and interpretation of the data: W. Stremmel, R. Ehehalt, M. Karner.
Drafting of the article: W. Stremmel, M. Karner.
Critical revision of the article for important intellectual content: W. Stremmel, M. Karner.
Final approval of the article: W. Stremmel, R. Ehehalt, F. Autschbach, M. Karner.
Provision of study materials or patients: W. Stremmel, F. Autschbach, M. Karner.
Statistical expertise: W. Stremmel, M. Karner.
Obtaining of funding: W. Stremmel.
Administrative, technical, or logistic support: W. Stremmel, R. Ehehalt, M. Karner.
Collection and assembly of data: W. Stremmel, R. Ehehalt, F. Autschbach, M. Karner.
Although long-term steroid treatment is discouraged in ulcerative colitis, alternatives are lacking when therapy with immunosuppressant drugs fails. An insufficient level of phosphatidylcholine in colonic mucus is a possible pathogenetic factor for ulcerative colitis.
To see whether steroid withdrawal is easier with retarded-release phosphatidylcholine or placebo in adults with chronic steroid-refractory ulcerative colitis.
Randomized, double-blind, placebo-controlled trial conducted from March 2003 to January 2006.
University Hospital Heidelberg, a referral center for inflammatory bowel disease.
60 patients with chronic steroid-refractory ulcerative colitis and high clinical and endoscopic disease activity indexes (score ≥5).
Phosphatidylcholine or cellulose placebo was ingested 4 times daily for 12 weeks for a total dosage of 2 g/d. The follow-up rate was 97%.
The number of patients achieving complete steroid withdrawal and either a low clinical activity index (≤3) or improvement in the clinical activity index of 50% or more.
The primary end point was achieved in 15 of 30 (50%) phosphatidylcholine recipients and in 3 of 30 (10%) placebo recipients (difference, 40% [95% CI, 19% to 61%]; P = 0.002). Twenty-four phosphatidylcholine recipients (80%) and 3 (10%) placebo recipients discontinued steroid therapy without disease exacerbation (difference, 70% [CI, 52% to 88%]; P <0.001). Mild bloating was a common adverse event.
The sample size was small, and the study was of short duration.
Phosphatidylcholine reduced corticosteroid dependence more than placebo in patients with chronic steroid-refractory ulcerative colitis. The next step is long-term trials to evaluate the sustainability of steroid withdrawal in these patients.
ClinicalTrials.gov registration number: NCT00259545.
Learn more about subscription options.
Register Now for a free account.
Stremmel W, Ehehalt R, Autschbach F, Karner M. Phosphatidylcholine for Steroid-Refractory Chronic Ulcerative Colitis: A Randomized Trial. Ann Intern Med. 2007;147:603–610. doi: 10.7326/0003-4819-147-9-200711060-00004
Download citation file:
Published: Ann Intern Med. 2007;147(9):603-610.
Endocrine and Metabolism, Gastroenterology/Hepatology, Inflammatory Bowel Disease.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only